AstraZeneca creating 700 new jobs with major expansion in Canada

The investment will support the move to a larger, state-of-the-art office facility in the Greater Toronto Area (GTA) in Ontario.

The move will contribute to AstraZeneca’s global ambition to achieve US$80 billion in total revenue and bring 20 new medicines to patients around the world by 2030. Eight new medicines have already been delivered and AZ also expects seven first Phase III clinical trial data readouts in 2025.

AstraZeneca is one of the leading R & D investors in Canada, contributing more than C$230 million in R & D in 2023, much of which is focused on delivery of over 210 AstraZeneca global clinical studies of new medicines and indications.

The company’s investments in Canada since 2023 now exceed C$1.3 billion, creating a combined 1,200 new high-skilled jobs. In 2024, AstraZeneca completed a C$3 billion agreement to acquire Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates with the promise to redefine radiotherapy for cancer patients. The Fusion announcement represents one of the largest research investments made in a Canadian biotech.

AstraZeneca CEO Pascal Soriot said: “This investment is a reflection of our growing clinical pipeline, our strong belief in Canada’s potential as a global hub for life sciences innovation and the value of public-private collaboration with the Ontario government.

“We believe the diverse talent pool together with the network of world-class universities, hospitals, and research centres will help us bring new medicines to Canadians and patients worldwide.”